Clinical Trials Browser

Unknown × Afatinib × Thoracic × Clear all

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04814056 2021-04-01

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Phase 4 Unknown

NRG1-fused Non-small Cell Lung Cancer

NCT04448379 2020-12-28

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04575415 2020-10-20

BELLA

NSCLC

NCT01746251 2020-07-07

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT03810872 2019-01-22

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Phase 2 Unknown

SarcomaThoracic

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Phase 1/2 Unknown

NSCLC

NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Phase NA Unknown

EGFR Mutation Positive Non-small Cell Lung Cancer